Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 4
2015 3
2016 3
2017 3
2018 4
2019 3
2020 5
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for hong thai pham
Search for Hoang Hai Pham instead (1 results)
Epidermal micro-perforation potentiates the efficacy of epicutaneous vaccination.
Hervé PL, Dhelft V, Plaquet C, Rousseaux A, Bouzereau A, Gaulme L, Tilleul S, Ligouis M, Donne N, Lambert PH, Hong-Thai P, Wijagkanalan W, Sampson HA, Mondoulet L. Hervé PL, et al. Among authors: hong thai p. J Control Release. 2019 Mar 28;298:12-26. doi: 10.1016/j.jconrel.2019.02.004. Epub 2019 Feb 6. J Control Release. 2019. PMID: 30738084
Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
Pagliusi S, Jarrett S, Hayman B, Kreysa U, Prasad SD, Reers M, Hong Thai P, Wu K, Zhang YT, Baek YO, Kumar A, Evtushenko A, Jadhav S, Meng W, Dat DT, Huang W, Desai S. Pagliusi S, et al. Among authors: hong thai p. Vaccine. 2020 Jul 22;38(34):5418-5423. doi: 10.1016/j.vaccine.2020.06.022. Epub 2020 Jun 11. Vaccine. 2020. PMID: 32600908 Free PMC article.
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
Chokephaibulkit K, Puthanakit T, Bhat N, Mansouri S, Tang Y, Lapphra K, Rungmaitree S, Anugulruengkitt S, Jantarabenjakul W, Andi-Lolo I, Holt R, Fortuna L, Kerdsomboon C, Chinwangso P, Suwitruengrit L, van den Biggelaar AHJ, Viviani S, Pham HT, Innis BL. Chokephaibulkit K, et al. Among authors: pham ht. Vaccine. 2022 Apr 1;40(15):2352-2361. doi: 10.1016/j.vaccine.2021.10.076. Epub 2021 Nov 14. Vaccine. 2022. PMID: 34789403 Free PMC article. Clinical Trial.
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C, Chanthavanich P, Limkittikul K, Siegrist CA, Wijagkanalan W, Chinwangso P, Petre J, Hong Thai P, Chauhan M, Viviani S. Sirivichayakul C, et al. Among authors: hong thai p. Hum Vaccin Immunother. 2017 Jan 2;13(1):136-143. doi: 10.1080/21645515.2016.1234555. Epub 2016 Sep 29. Hum Vaccin Immunother. 2017. PMID: 27686283 Free PMC article. Clinical Trial.
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G, Chatzis O, Chinwangso P, Rohr M, Grillet S, Salomon C, Lemaître B, Boonrak P, Lawpoolsri S, Clutterbuck E, Poredi IK, Wijagkanalan W, Spiegel J, Pham HT, Viviani S, Siegrist CA. Blanchard Rohner G, et al. Among authors: pham ht. Clin Infect Dis. 2019 Mar 19;68(7):1213-1222. doi: 10.1093/cid/ciy594. Clin Infect Dis. 2019. PMID: 30759183 Clinical Trial.
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
Fortuna L, Chaithongwongwatthana S, Soonthornworasiri N, Spiegel J, Wijagkanalan W, Mansouri S, van den Biggelaar AHJ, Pham HT. Fortuna L, et al. Among authors: pham ht. Vaccine. 2020 Dec 3;38(51):8194-8199. doi: 10.1016/j.vaccine.2020.10.070. Epub 2020 Nov 8. Vaccine. 2020. PMID: 33176935 Free article.
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.
Pitisuttithum P, Dhitavat J, Sirivichayakul C, Pitisuthitham A, Sabmee Y, Chinwangso P, Kerdsomboon C, Fortuna L, Spiegel J, Chauhan M, Poredi IK, van den Biggelaar AHJ, Wijagkanalan W, Viviani S, Mansouri S, Pham HT. Pitisuttithum P, et al. Among authors: pham ht. EClinicalMedicine. 2021 Jun 23;37:100976. doi: 10.1016/j.eclinm.2021.100976. eCollection 2021 Jul. EClinicalMedicine. 2021. PMID: 34386749 Free PMC article.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani S. Pitisuttithum P, et al. Among authors: pham ht. Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25. Lancet Infect Dis. 2018. PMID: 30266329 Clinical Trial.
29 results